| Literature DB >> 22532090 |
Katarzyna Wiśniewska1, Anna Szewczyk, Lidia Piechowicz, Marek Bronk, Alfred Samet, Krystyna Swieć.
Abstract
The emergence of spa types and spa-clonal complexes (CC) among clinical methicillin-resistant Staphylococcus aureus isolates collected from the University Clinical Center in Gdańsk between 2008 and 2009 were investigated. Phage typing was used as the initial screening in the study. The basic set of phages and the additional set of phages were used. Most of the isolates (56 %) belonged to the phage group III. With the additional set of phages, eight types were found, with predominant one MR8 (50 %). Sixteen distinct spa types were observed. The most frequent were t003 (22 %), t151 (16 %), and t008 (12 %). The spa types were clustered into two spa-CC and eight singletons. The predominant CC010 (50 %) consisted of six types, with the most common t003 (36.7 %) and t151(26.7 %), and in 80 % was identified as staphylococcal chromosomal casette mec (SCCmec) type II. The second cluster has no founder (12 %) with only two spa types: t037 belonging to SCCmec type III and t029. In the most frequent singleton, spa type t008 alone was clustered in 12 % of the isolates. All singletons correspond to SCCmec type IV. The CC010 was distributed in most of the hospital wards, corresponded to Multilocus sequence typing type ST5/ST225 and was constantly present throughout the observed period. The isolates of CC010 generally belonged to the phage group III, and most of them (53.3 %) were resistant to erythromycin, clindamycin, and ciprofloxacin. The concordance between spa-clone and phage type was very high, but the same phage type MR8 was observed within different spa types of the predominant clone.Entities:
Mesh:
Year: 2012 PMID: 22532090 PMCID: PMC3345334 DOI: 10.1007/s12223-012-0148-z
Source DB: PubMed Journal: Folia Microbiol (Praha) ISSN: 0015-5632 Impact factor: 2.099
Results of phage typing of the 50 MRSA isolates
| Phage group | Number (%) of isolates | Phage type (basic set) | Number (%) of isolates | Phage type (additional set) | Number (%) of isolates |
|---|---|---|---|---|---|
| II | 3 (6) | 55 | 2 (4) | MR8 | 25 (50) |
| 55/71 | 1 (2) | MR25 | 4 (8) | ||
| III | 28 (56) | 54/75/83A | 10 (20) | 622 | 3 (6) |
| 75/83A | 5 (10) | MR8/MR12 | 1 (2) | ||
| 47/54/75/83A | 3 (6) | M8/MR25 | 1 (2) | ||
| 83A | 3 (6) | MR8/MR12/MR25 | 1 (2) | ||
| 53/83A | 2 (4) | M3 | 1 (2) | ||
| 75 | 2 (4) | MR25°/M5° | 1 (2) | ||
| 6 | 1 (2) | NT | 13 (26) | ||
| 47/75 | 1 (2) | ||||
| 42E/53/75/83A | 2 (4) | ||||
| Mixed group: | 2 (4) | ||||
| I/II/III | 52A/3 C/55/84 | 1 (2) | |||
| I/V | 55/94/96 | 1 (2) | |||
| Inhibition | 2 (4) | 88 °/89 ° | 1 (2) | ||
| 55 ° | 1 (2) | ||||
| Non-typable | 15 (30) | NT | 15 (30) |
Frequency of resistance to antimicrobial agents among the 50 MRSA isolates
| Antimicrobial agent: | E | Cc | Cip | Te | C | Sxt | Ge | Rf |
|---|---|---|---|---|---|---|---|---|
| Number of resistant strains (%) | 38 (76) | 37 (74) | 43 (86) | 21 (42) | 16 (32) | 5 (10) | 8 (16) | 1 (2) |
E erythromycin, Cc clindamycin, Cip ciprofloxacin, Te tetracycline, C chloramphenicol, Sxt co-trimoxazole, Ge gentamicin, Rf rifampicin
Results of spa-typing and Spa-complex analysis of 50 MRSA isolates in correlation with SCCmec type
|
| Number (%) of isolates |
| Scc |
|---|---|---|---|
| CC 010 | 30 (60) | t 003 (11) | II |
| t 151 (8) | II | ||
| t 002 (5) | II | ||
| t 2065 (3) | IV | ||
| t 045 (2) | IV | ||
| t 010 (1) | IV | ||
| No founder | 6 (12) | t 037 (5) | III |
| t 029 (1) | IV | ||
| Singleton #1 | 6 (12) | t 008 (6) | IV |
| Singleton #2 | 1 (2) | t 018 (1) | IV |
| Singleton #3 | 1 (2) | t 032 (1) | IV |
| Singleton #4 | 1 (2) | t 127 (1) | IV |
| Singleton #5 | 1 (2) | t 346 (1) | IV |
| Singleton #6 | 2 (4) | t 437 (2) | IV |
| Singleton #7 | 1 (2) | t 899 (1) | IV |
| Singleton #8 | 1 (2) | t 1328 (1) | IV |
Characteristic of the 30 MRSA isolates belonging to spa-CC010 by the results of phage typing and antibiotic resistance patterns analysis
| Isolate | Date of isolation | Ward/clinical department | Clinical specimen | Antibiotic resistance | Phage group | Phage type (basic set) | Phage type (additional) |
|
|---|---|---|---|---|---|---|---|---|
| 1 | 20.03 | Plastic surgery | Burn wound | Cip Te C | III | 6 | 622 | t2065 |
| 2 | 12.03 | Pediatric nefrology | Skin | Cip Te | NT | NT | NT | t045 |
| 3 | 18.05 | DWA | Sputum | Cip Te C | III | 75 | NT | t2065 |
| 4 | 6.06 | Neurology | Blood | E Cc Cip | III | 75/83A | MR8 | t003 |
| 5 | 11.06 | DWA | Urine | Te C | III | 42E/53/75/83A | 622 | t010 |
| 6 | 19.06 | Neonatology | Eye | E /Cc Cip | III | 83A | MR8 | t002 |
| 7 | 20.08 | Neurology | Nose | E Cc Cip | III | 83A | MR8 | t002 |
| 8 | 29.08 | Pediatric nefrology | Catheter ostium | Cip Te | NT | NT | NT | t045 |
| 9 | 2.09 | Pneumology | Wound | E Cc Cip | III | 83A | MR8 | t002 |
| 10 | 5.09 | Pneumology | BAL | E Cc Cip C | III | 54/75/83A | MR8 | t151 |
| 11 | 6.09 | DWA | Throat | E Cc Cip C | III | 54/75/83A | MR8 | t151 |
| 12 | 8.09 | Neonatology | Anus | E Cc Cip C | III | 54/75/83A | MR8 | t151 |
| 13 | 9.09 | DWA | Nose | E Cc Cip C | III | 54/75/83A | MR8 | t151 |
| 14 | 10.09 | Neurology | Bronchial fluid | E Cc Cip | III | 54/75/83A | MR8 | t003 |
| 15 | 15.09 | Cardiosurgery | Wound | E Cc Cip | III | 54/75/83A | MR8 | t003 |
| 16 | 19.09 | ICU | Nose | E Cc Cip | III | 54/75/83A | MR8 | t003 |
| 17 | 22.09 | Neurology | Tracheostomy tube | E Cc Cip | III | 47/54/75/83A | MR8 | t003 |
| 18 | 4.10 | Neurology | Sputum | E Cc Cip | III | 47/75 | MR8 | t003 |
| 19 | 12.10 | No data | Abscess | E Cc Cip | III | 75/83A | MR8 | t003 |
| 20 | 28.10 | Trauma surgery | Nose | E Cc Cip | III | 75/83A | MR8 | t003 |
| 21 | 28.10 | DWA | Wound | Cip Te C | III | 53/83A | 622 | t2065 |
| 22 | 13.11 | Plastic surgery | Wound | E Cc Cip | II | 55/71 | MR8 | t003 |
| 23 | 24.11 | Plastic surgery | Bedsore | E Cc Cip | III | 54/75/83A | MR8 | t003 |
| 24 | 18.01 | ICU | BAL | E Cc Cip C | III | 75/83A | MR8 | t151 |
| 25 | 27.01 | Trauma surgery | Tracheostomy tube | E Cc Cip C | III | 47/54/75/83A | MR8 | t151 |
| 26 | 8.02 | Neurosurgery | Wound | E Cc Cip | III | 83A | MR8/MR12 | t003 |
| 27 | 24.02 | DWA | Nose | E Cc Cip C | III | 54/75/83A | MR8 | t151 |
| 28 | 17.03 | Hematology | Anus | E Cc Cip C | III | 54/75/83A | MR8 | t151 |
| 29 | 31.03 | Trauma surgery | Wound | E Cc Cip | NT | NT | MR8 | t002 |
| 30 | 3.04 | Trauma surgery | Wound | E Cc Cip | NT | NT | MR8 | t002 |
ICU Intensive Care Unit, DWA dermatology, venerology, allergology/inducible resistance to macrolides